Cristália Produtos Químicos Farmacêuticos Ltda.

This early-stage trial tests whether a single dose of CRIS100 is safe for people with a recent spinal cord injury in the upper back. Only 5 adults with severe injuries will receive the drug directly at the injury site within 72 hours. The study focuses on side effects and lab cha…

This early-stage study tests a new liposome-based antidote in 12 healthy adults aged 18-30. The goal is to check safety and how the body processes the drug, not to treat any disease. Participants must be in good health and avoid pregnancy during the study.